Author of

• 25971

  +

  P3.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session) (ID 983)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27811

    +

    P3.17-19 - First Relapse and Survival Five Years After Radical Radiotherapy for Lung Cancer. (ID 13501)

    12:00 - 13:30  |  Presenting Author(s): Gerard Walls
    • Abstract
    • Slides

    Background
    

    Whilst local and distant control rates for both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) have been described for the immediate years following curative-intent radiotherapy, the natural history in patients with long-term disease-free survival (DFS) has not been established. Late relapse has been described in limited, small series (e.g. following surgery or SABR) but there is a paucity of data on relapse and survival after radical radiotherapy for all-comers. With improved radiotherapy planning and delivery, systemic therapy personalisation and surveillance strategies, survival rates at five years are improving. We describe the outcomes in patients with at least five years DFS from the commencement of radiotherapy.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    Patients with DFS >5 years post-radiotherapy between 1^st December 2000 and 1^st March 2013 were identified from a prospective database of patients treated with curative-intent radiotherapy at a tertiary centre. Electronic records were interrogated for information pertaining to disease status and cause of death.

    4c3880bb027f159e801041b1021e88e8 Result
    

    680 patients received curative-intent radiotherapy; 503 NSCLC, 176 SCLC. At 5 years, 108 (16%) patients were alive; 66 males, 42 females. Mean age of survivors at treatment 67 years, median ECOG PS 1. SCLC for accounted 32 cases (18% total SCLC); NSCLC for accounted 76 cases (15% total NSCLC). SCLC (n=32 limited-stage) were managed with sequential chemoradiotherapy (n=20), concurrent chemoradiation (n=12). NSCLC (n=37 stage I; n=9 stage II; n=27 stage III; n=3 stage IV) were managed with radiotherapy alone (n=47), sequential chemoradiotherapy (n=19), concurrent chemoradiotherapy (n=7), SABR (n=5). With 80 months total median follow-up 16 (15%) patients surviving 5 years relapsed, 14 NSCLC (2.7% total treated radically), 2 SCLC (1.9% total treated radically). Of 23 patients reaching the 5-year time-point and thereafter developing a further malignancy, 4 were cases of second lung primary.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Approximately 1 in 6 patients (all-comers) survived for 5 years after radical radiotherapy. Approximately 1 in 6 patients with 5 year DFS will later go on to relapse, suggesting that such patients should receive active follow-up.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.